BioCardia, Inc. (BCDA): Capital Expenditures
$7.0K
Year ended 2025-12-31
$9.0K
Trailing 12 months to 2026-06-30
-53.6%
3-year compound annual growth
-26.2%
5-year compound annual growth
-25.0%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.0K | +16.7% | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | $6.0K | -50.0% | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | $12.0K | -82.9% | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $70.0K | -39.7% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $116.0K | +262.5% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $32.0K | -78.1% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $146.0K | +121.2% | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | $66.0K | -51.5% | 2020-04-09, From 2018-01-01 |
| 2017-12-31 | $136.0K | n/a | 2020-04-09, From 2017-01-01 |
| No annual figure between 2015-12-31 and 2017-12-31. | |||
| 2015-12-31 | $125.0K | n/a | 2018-03-16, From 2015-01-01 |
| No annual figure between 2012-12-31 and 2015-12-31. | |||
| 2012-12-31 | $0 | -100.0% | 2013-03-22, From 2012-01-01 |
| 2011-12-31 | $137.0K | -87.2% | 2013-03-22, From 2011-01-01 |
| 2010-12-31 | $1.07M | n/a | 2012-03-29, From 2010-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | 2025-12-31 | $7.0K | +16.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $145.0K | -73.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $1.86B | +69.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $23.52M | -8.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $564.0K | +45.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
| Biogen Inc. (BIIB) | 2025-12-31 | $153.80M | +0.1% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $563.00M | +7.6% |
Compare BCDA, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗